Tumor Models Market Report 2026

The tumor models market size has grown rapidly in recent years. It will grow from $2.13 billion in 2025 to $2.37 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to limited availability of advanced tumor models, reliance on traditional 2D cell cultures, growing cancer research funding, increasing prevalence of cancer, adoption of orthotopic and heterotopic models.

The tumor models market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to advancements in organ-on-a-chip and 3D spheroid technologies, increasing focus on personalized oncology treatments, expansion of contract research organizations (cros) in tumor research, rising pharmaceutical R&D expenditure, integration of ai and big data analytics in tumor model studies. Major trends in the forecast period include increasing use of 3D tumor spheroids and organ-on-a-chip models, rising demand for personalized medicine and targeted cancer therapies, expansion of xenograft and genetically engineered mouse models (gemms), growth in drug discovery and toxicology studies using tumor models, collaboration between pharmaceutical companies and academic institutions.

The escalating demand for personalized medicine is poised to accelerate the tumor models market ahead. Personalized medicine leverages a person's genetic data and lifestyle factors to customize treatments and care to their distinct profile. Its growth stems from preferences for health tech delivering live monitoring and biology-matched therapy plans. Tumor models aid personalized medicine by letting researchers and doctors simulate and forecast patient tumor reactions to therapies via platforms mirroring actual human cancers, fostering bespoke treatment strategies. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a marked rise from 12 in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the tumor models market.

Prominent companies in the tumor models market are advancing sophisticated tools like tumor spheroid models to boost biological fidelity and forecasting power of lab-based cancer simulations. Tumor spheroid models are three-dimensional (3D) clusters of cancer cells forming round structures in culture. For instance, in June 2024, Predictive Oncology, a US-based provider of advanced 3D cell culture technologies and predictive oncology solutions, introduced cutting-edge 3D cell technology to hasten cancer drug discovery. It features refined 3D tumor spheroid and organoid setups replicating the tumor milieu, rapid screening for swift drug trials, patient-sourced custom tumor replicas, in-depth drug infiltration analysis in 3D setups, and AI-powered analytics for sharper predictions and richer therapy response insights.

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences for an undisclosed amount. Through this acquisition, Merck seeks to fortify its oncology offerings by weaving in Modifi's targeted small-molecule treatments hitting DNA repair-weak cancer cells, zeroing in on tough cases like glioblastomas. Modifi Biosciences Inc. is a US-based biotechnology company that specializes in tumor models.

Major companies operating in the tumor models market are WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Pharmaron Beijing Co. Ltd., The Jackson Laboratory, Taconic Biosciences Inc., Cyagen Biosciences Inc., Crown Bioscience Inc., Champions Oncology Inc., InSphero AG, Creative Biolabs Inc., Oncodesign S.A., Xentech S.A., MIMETAS BV, Experimental Pharmacology and Oncology Berlin-Buch GmbH.

North America was the largest region in the tumor models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the tumor models market by increasing the cost of imported laboratory equipment, reagents, and specialized animal models. Segments like xenograft models and genetically engineered mouse models (GEMMs) are most affected, particularly in North America and Europe, where imports from Asia-Pacific constitute a significant portion of supplies. This has led to higher operational costs and potential delays in research activities. However, tariffs have also encouraged local production of lab models, development of cost-efficient alternatives, and increased investment in domestic research infrastructure.

The tumor models market research report is one of a series of new reports that provides tumor models market statistics, including tumor models industry global market size, regional shares, competitors with a tumor models market share, detailed tumor models market segments, market trends and opportunities, and any further data you may need to thrive in the tumor models industry. This tumor models market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tumor models are experimental biological systems designed to replicate the characteristics and behavior of tumors in living organisms. They mimic the cellular composition, molecular features, and growth patterns of cancer, as well as its interactions with the surrounding environment. These models allow researchers to study tumor development and progression in a controlled setting, supporting a deeper understanding of cancer biology.

The main types of tumor models are primary tumor models, metastatic tumor models, orthotopic tumor models, and heterotopic tumor models. Primary tumor models are developed by implanting or inducing cancer cells at the site where the tumor naturally originates in the body. These models are applied in drug discovery and development, cancer research, personalized medicine, and toxicology studies. They utilize technologies such as xenograft models, genetically engineered mouse models (GEMMs), three-dimensional (3D) tumor spheroids, and organ-on-a-chip models. Key end users include pharmaceutical and biotechnology companies, academic institutions, contract research organizations (CROs), and government research organizations.

The tumor models market includes revenues earned by entities by providing services such as drug screening and efficacy testing, tumor biology research, biomarker discovery and validation, toxicology and safety testing, and immuno-oncology studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor models market also includes sales of cancer cell lines, in vitro tumor models, imaging systems, tumor model kits, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.